Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Vivesto AB banner

Vivesto AB
STO:VIVE

Watchlist Manager
Vivesto AB Logo
Vivesto AB
STO:VIVE
Watchlist
Price: 0.0864 SEK 4.47%
Market Cap: kr93.2m
Write Note Create Alert Ask AI

Vivesto AB
Investor Relations

Oasmia Pharmaceutical AB engages in the research and development of drugs. The company is headquartered in Solna, Stockholm. The company went IPO on 2005-01-01. The firm has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Show more
Loading
VIVE
OMX Stockholm 30
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.
Chief Executive Officer
No Bio Available
Mr. Robert Maiorana
Head of Accounting & Acting CFO
No Bio Available
Mr. Urban Ekelund
IR Manager
No Bio Available
Mr. Dzianis Babrou
Head of Product Development
No Bio Available
Mr. Henrik Rönnberg
Chief Medical Officer of Animal Health
No Bio Available
Maria Nilsson Hagberg
Head of Regulatory Affairs
No Bio Available
Dr. Heidi B. Ramstad
Chief Medical Officer
No Bio Available
Ms. Johanna Rostin
Chief Regulatory Officer
No Bio Available
Ms. Kia Bengtsson
Head of Clinical Development
No Bio Available

Contacts

Address
STOCKHOLM
Solna
Gustav III:s Boulevard 46, 5tr
Contacts
+4618505440.0
www.vivesto.com
sparklesyt

See Also

Summary
VIVE intrinsic value, competitors valuation, and company profile.
DCF Valuation
VIVE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VIVE stock valuation using valuation multiples.
Wall Street Estimates
VIVE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VIVE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 316,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.